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Inhibition of TNF-a Improves the Bladder Dysfunction
That Is Associated With Type 2 Diabetes
Zongwei Wang,1 Zhiyong Cheng,2 Vivian Cristofaro,3 Jijun Li,1,4 Xingyuan Xiao,1,5 Pablo Gomez,6
Rongbin Ge,1 Edward Gong,6 Klemen Strle,7 Maryrose P. Sullivan,3 Rosalyn M. Adam,6
Morris F. White,2 and Aria F. Olumi1
Diabetic bladder dysfunction (DBD) is common and affects 80%
of diabetic patients. However, the molecular mechanisms un-
derlying DBD remain elusive because of a lack of appropriate
animal models. We demonstrate DBD in a mouse model that
harbors hepatic-speciﬁc insulin receptor substrate 1 and 2 dele-
tions (double knockout [DKO]), which develops type 2 diabetes.
Bladders of DKO animals exhibited detrusor overactivity at an
early stage: increased frequency of nonvoiding contractions dur-
ing bladder ﬁlling, decreased voided volume, and dispersed urine
spot patterns. In contrast, older animals with diabetes exhibited
detrusor hypoactivity, ﬁndings consistent with clinical features of
diabetes in humans. The tumor necrosis factor (TNF) superfamily
genes were upregulated in DKO bladders. In particular, TNF-a
was upregulated in serum and in bladder smooth muscle tissue.
TNF-a augmented the contraction of primary cultured bladder
smooth muscle cells through upregulating Rho kinase activity
and phosphorylating myosin light chain. Systemic treatment of
DKO animals with soluble TNF receptor 1 (TNFRI) prevented
upregulation of Rho A signaling and reversed the bladder dysfunc-
tion, without affecting hyperglycemia. TNFRI combined with
the antidiabetic agent, metformin, improved DBD beyond that
achieved with metformin alone, suggesting that therapies target-
ing TNF-a may have utility in reversing the secondary urologic
complications of type 2 diabetes. Diabetes 61:2134–2145, 2012
Diabetes is reaching epidemic proportions andcurrently affects 8.3% of the U.S. population (1).Annually, 1.5 million new cases of diabetes arediagnosed. Type 2 diabetes accounts for 90% of
newly diagnosed cases in the U.S. and is associated with
chronic hyperglycemia. Deleterious complications of type 2
diabetes include heart disease, stroke, hypertension, reti-
nopathy, neuropathy, nephropathy, and complications dur-
ing pregnancy. From a urologic standpoint, patients with
type 2 diabetes present with signiﬁcant voiding complaints,
recurrent urinary tract infections, and erectile dysfunc-
tion (2). Diabetic bladder dysfunction (DBD) is a common
complication, affecting up to 80% of patients with diabetes
(3), and causes a range of voiding and storage symptoms.
Early DBD in compensated stages is frequently not rec-
ognized by patients or physicians due to its insidious de-
velopment and inconspicuous symptoms; thus, by the time
urologists are consulted, the DBD in diabetic patients has
often reached an advanced stage in which the bladder is
ﬂaccid and poorly contractile (4).
DBD is traditionally described as a triad of decreased
sensation, increased capacity, and poor emptying (5).
However, recent clinical evidence indicates a more com-
plex spectrum of bladder dysfunctions in patients with
diabetes, including detrusor overactivity with or without
urinary incontinence, impaired detrusor contractility, and
detrusor areﬂexia (6). A multifactorial pathophysiology is
supported by studies that have revealed disturbances of
the bladder detrusor muscle, urethra, autonomic nerves,
and urothelium (6,7).
Studies on streptozotocin (STZ)-induced type 1 diabetes
suggest that DBD comprises two phases: a compensatory
phase that occurs soon after the onset of diabetes and is
characterized by bladder hypertrophy, remodeling, in-
creased contractility, and associated neurogenic changes,
followed by a decompensated phase that develops at later
stages of diabetes featuring decreased peak voiding pres-
sure (6,8,9). Despite signiﬁcant recent advances in under-
standing the pathophysiology of DBD, the underlying
molecular pathways that contribute to the secondary blad-
der complications of type 2 diabetes are poorly understood.
Patients are generally treated with hypoglycemic medi-
cations and muscarinic receptor antagonists to ameliorate
the symptoms of overactive bladder. However, the under-
lying molecular alterations that can potentially be used for
targeted therapies or identiﬁcation of patients at risk for
developing late stage are poorly understood. To investigate
the molecular pathways associated with DBD, we used an
animal model with conditional (cre-lox) hepatic double-
knockout (DKO) of Irs1 and Irs2 genes (10,11). In this
study, we show for the ﬁrst time, that DKO mice developed
bladder hyperactivity at age 6–12 weeks but showed
bladder hypoactivity at age 16–20 weeks, a ﬁnding that
parallels the variable and potentially temporal pathophys-
iologic alterations in bladder function in patients with type
2 diabetes. Furthermore, we discovered elevated levels of
circulating and bladder tissue–associated TNF-a. We dem-
onstrate that TNF-a directly stimulates bladder smooth
muscle cell (BSMC) contraction, which can account for
the bladder hyperactivity of the young DKO mice. We
show that TNF-a activates Rho kinase (ROCK)–myosin
light chain kinase (MLCK)–phosphorylating myosin light
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chain (pMLC) signaling, a pathway that when altered is
known to cause bladder smooth muscle hypercontractility
(12). More important, systemic inhibition of TNF-a–mediated
signaling in mice reverses the DBD without affecting hy-
perglycemia in these animals. The combination of TNF-a
inhibition and oral hypoglycemic therapy with metformin
improves secondary urologic complications of DBD to a
greater extent than that observed with metformin alone.
Together, our ﬁndings suggest that targeted inhibition of
the TNF-a pathway may have a role in treating DBD and
reducing the burden of the secondary complications of
type 2 diabetes.
RESEARCH DESIGN AND METHODS
Generation of DKO mice. The ﬂoxed Irs1, Irs2 mice were generated as
previously reported (10,11,13). To generate liver-speciﬁc knockout mice,
ﬂoxed Irs1 and Irs2 mice were crossed with albumin-Cre mice (The Jackson
Laboratory). The Irs1KO, Irs2KO and their corresponding control ﬂoxed mice
were maintained on a C57/BL6 and 129Sv mixed genetic background. To avoid
any potential obstructive effect of the prostate on the bladder, we used female
DKO animals and their female littermates as control for these studies. All
animal experiments were performed according to procedures approved by the
Institutional Animal Care and Use Committee at Massachusetts General Hospital,
Children’s Hospital Boston.
Cystometric evaluation of bladder function in vivo. General anesthesia
was induced by intraperitoneal injection of ketamine (100 mg/kg) and xylazine
(10 mg/kg), the animal’s bladder was surgically exposed, and a 25-gauge
needle was introduced into the dome of the bladder and connected via a three-
way adapter to a ﬂuid-ﬁlled pressure line at one end and an injection pump
(Harvard Apparatus) at the other. The pressure line was connected to
a physiologic pressure transducer (MLT844 AD Instruments), and the bladder
was ﬁlled with sterile saline at a constant rate (15 mL/min). The output signal
was ampliﬁed and recorded using the Windaq system (Dataq Instruments)
(14,15).
Voided stain on paper (VSOP) analysis. Mice were placed individually in
metabolic cages with available food and water and allowed to adapt to their
new environment for 24 h. Urine output wasmeasured by evaluating the surface
area of the stained VSOP paper (Bio-Rad) 3 h after the mice were placed in the
metabolic cages. Collected papers were imaged under ultraviolet light to vi-
sualize the urine and analyzed by using the edge-detection function of ImageJ
software (National Institutes of Health [NIH]) to identify the surface area of
individual voided urine spots. The volumes of individual voids were calculated
based on a calibration curve relating surface area to ﬂuid drops of known
volume (14,15).
Assessment of bladder smooth muscle contractility. Full-thickness lon-
gitudinal detrusor muscle strips (0.7 to 1 3 3.5 to 5 mm) were prepared and
transferred to 5 mL tissue baths containing Kreb’s solution bubbled with
a mixture of oxygen (95%) and carbon dioxide (5%). One end of each strip of
tissue was tied by silk suture to a ﬁxed hook and the other to a force trans-
ducer. Bladder tissue was stretched to a passive tension of 0.5 g and allowed
to equilibrate for 60 min before experiments were performed. The frequency
and amplitude of spontaneous activity was determined over a 5-min interval
after the equilibration period. In addition, the contractile response to stimula-
tion of bladder tissue by potassium chloride (KCl) (120 mmol/L) and electrical
ﬁeld stimulation (EFS; 2, 4, 8, 16, 32, 64 Hz; 40 V; 0.5 ms pulse duration for 10 s)
was measured. The dose-response curve for carbachol was generated by adding
cumulative concentrations of the agonist (1029 to 1025 mol/L) to the bath.
Isometric force was continuously recorded with a computerized data acquisi-
tion program at a sampling rate of 20 Hz. At the end of experiments, the weight,
length, and width of each strip was measured to normalize the force data (16).
Affymetrix gene array analysis. The Affymetrix GeneChip analysis was
performed as previously described (10,11). Brieﬂy, total RNA was extracted
from bladder smooth muscle tissues using the RNeasy Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. Microarray anal-
ysis was conducted by the Harvard Partners HealthCare Center for Person-
alized Genetic Medicine Microarray Facility using 15 mg RNA from each
sample, with each group in triplicate. Gene expression was analyzed by using
Mouse Genome 430 2.0 array system (Affymetrix). The Database for Annota-
tion, Visualization and Integrated Discovery (DAVID Bioinformatics Resources
6.7, NIH) was used to categorize the most signiﬁcantly changed genes (upreg-
ulated 1.5-fold or more relative to age-matched control) by biologic functions or
disease processes.
BSMC isolation, culture, and transfection. Rat BSMCs were isolated from
1-week-old Sprague-Dawley female rats, as described previously (17). The cell
pellet was resuspended in medium 199 (Gibco) and used for experiments up to
passage 3. For gene suppression experiments, BSMCs were transfected with
small interfering (si)RNA at 40% conﬂuency using silMPORTER transfection
reagent (Millipore), according to the manufacturer’s instructions.
Collagen gel retraction assay. Collagen lattice was carefully prepared in
24-well plate by collagen type 1 from rat tail (Sigma) (18). A total of 25,000
BSMCs were layered onto each collagen lattice and left to settle for 2 h at
37°C. To allow contraction, each collagen lattice was detached from the
bottom of the well with a small spatula and left overnight at 37°C. Contraction
was stopped by ﬁxing the lattices in PBS-4% paraformaldehyde, and the plate
was photographed. Image analyses of the gel area were performed by using
ImageJ software (NIH).
Western blot analysis. Immunoblotting was performed as previously de-
scribed (19). To stimulate the phosphorylation of MLC, bladder smooth muscle
tissues were treated with 80 mmol/L KCl for 15 s and then quickly frozen in
liquid nitrogen (20), and cultured BSMCs were treated with 80 mmol/L KCl for
5 min. Total protein was quickly extracted on ice (21), and the protein extracts
were subjected to SDS-PAGE and blotted. Membranes were probed with tar-
get antibodies.
Immunostaining. As described previously (22), sections (5 mm) from parafﬁn-
embedded tissue underwent antigen retrieval with proteinase K (Dako) and
were incubated with primary and secondary antibody. Cells grown on glass
coverslips were ﬁxed in 4% paraformaldehyde, permeabilized with 0.2% Triton
X-100/PBS, and stained with antibodies (23).
Evaluation of the activity of ROCK1 or ROCK2 in cell lysates. Activation
of ROCK1 or ROCK2 was evaluated by immunoprecipitating ROCK1 or ROCK2,
followed by an in vitro kinase activity assay (24). Cells were lysed using cell
lysis buffer (Cell Signaling), and cleared lysates were incubated for 1 h at 4°C
with 2 mg isotype control IgG, anti-ROCK1, or anti-ROCK2 (Santa Cruz). The
mixture was incubated with protein A/G agarose beads at 4°C overnight. The
beads were pelleted, washed, and incubated for 30 min at 30°C with kinase
reaction buffer containing 200 mmol/L ATP (Cell Signaling) and 0.5 mg puriﬁed
myosin phosphatase target subunit 1 (MYPT-1; Millipore), a ROCK-speciﬁc
substrate. The reaction was terminated by boiling the samples in SDS. The
amount of phosphorylated MYPT-1 or immunoprecipitated ROCK1 or ROCK2
was examined using immunoblot.
ROCK activity assay in animal tissue. ROCK enzymatic activity was de-
termined with a commercially available Cyclex Rho kinase Assay Kit-96 (MBL
International) (25).
Cytokine assay. Cytokine productions were analyzed with a Milliplex Map Kit
for mouse cytokine assay (Millipore) according to the manufacturer’s instruc-
tions, which allowed the simultaneous quantiﬁcation of the following mouse
cytokines: granulocyte-macrophage colony-stimulating factor, interferon-g, in-
terleukin (IL)-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12(p70), and TNF-a. In anti-
TNF receptor (TNFR) treatment experiments, the level of TNF-a in serum
was determined using commercial mouse TNF-a ELISA Kit (eBioscience)
according to the manufacturer’s protocol.
Blood glucose analysis. Blood glucose levels were measured using a portable
glucometer (Bayer). For glucose tolerance tests (GTT), mice were fasted
overnight and injected intraperitoneally with D-glucose (2 g/kg body weight),
and blood glucose levels were measured at indicated time points, as pre-
viously described (10).
RESULTS
Temporal alteration of DKO bladder function.We ﬁrst
evaluated whether the DKO mice exhibit alterations in blad-
der function and found that DKO mice exhibited signiﬁcantly
higher amplitudes of spontaneous activity at age 6 and 12
weeks relative to age-matched controls (Fig. 1A and B).
In contrast, 16- and 20-week-old DKO mice demonstrated
lower amplitudes of spontaneous activity than age-matched
controls (Fig. 1A and B). Meanwhile, the frequency of
spontaneous activity in the bladders did not vary (Fig. 1C).
The contractile responses of bladder tissue to KCl (120
mmol/L; Fig. 1D) and carbachol stimulation (1029 to ;1025
mol/L; Fig. 1E and F) were signiﬁcantly greater in young
DKO mice (age 6–12 weeks), but signiﬁcantly diminished in
20-week-old DKO mice compared with age-matched control
animals. However, the response to carbachol stimulation in
control mice was not different among age groups (Fig. 1F),
which ruled out the possibility of age-dependent changes in
cholinergic receptor sensitivity. We further induced neuro-
genically mediated bladder contractions by EFS (26,27) and
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found that the contractile response to EFS was augmented
in bladder tissue of 6- and 12-week-old DKO mice but di-
minished in older mice at ages 16 and 20 weeks (Supple-
mentary Table 1).
DKO mice showed an abnormal urine voiding pattern.
To gain further insight into the development of bladder
dysfunction associated with type 2 diabetes, we evaluated
the urinary voiding patterns in the DKO mice in vivo by
FIG. 1. DKO mice exhibit increased spontaneous and stimulated bladder contractions early in life and decreased contractions later in life.
A: Representative spontaneous contractions of bladder strips in ﬂoxed control (CTR) and liver-speciﬁc Irs1/Irs2 DKO mice. Quantiﬁcation
of the amplitude (B) and frequency (C) of spontaneous contraction. D: Bladder smooth muscle contraction induced by KCl (120 mmol/L)
stimulation in DKO and CTR mice. Bladder smooth muscle contraction induced by carbachol (Carb) stimulation at 1025 mol/L (E) and 1029 to
;1025 mol/L (F). The tension data were obtained from eight strips from four animals in each group and normalized by the length, width, and
weight of muscle strips. Bladder tissue was stretched to a passive tension of 0.5 g and allowed to equilibrate for 45 to ;60 min before
experiments were performed. Isometric force was continuously recorded with a computerized data acquisition program at a sampling rate of
20 Hz. CTR indicates the littermate combined ﬂoxed Irs1 and Irs2 gene control animal. Data are representative of at least three different
experiments and are expressed as the means 6 SEM, by unpaired Student t test. *P < 0.05 and **P < 0.01 compared with age-matched control
group. w, weeks.
TNF-a INHIBITION IMPROVES DBD
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performing cystometry and VSOP analysis. During cys-
tometry, the voiding pattern in DKO mice was markedly
altered. Although the micturition frequency did not change
signiﬁcantly (Fig. 2A and B), 12-week-old DKO animals
exhibited clear signs of bladder overactivity, characterized
by increased frequency of nonvoiding contractions and
signiﬁcantly reduced voided volumes (Fig. 2C and E). For
20-week-old DKO animals, however, the amplitude of
FIG. 2. DKO animals exhibit abnormal voiding pattern. A: Original cystometric recordings in control (CTR) and DKO mice at the age of 12 and 20
weeks (w). Arrowheads reﬂect abnormal bladder contractions not associated with urination. Evaluation of urodynamic parameters: frequency of
voiding contractions (VC) (B), frequency of nonvoiding contractions (NVC) (C), amplitude of the detrusor contraction during voiding (Pdetmax)
(D), and voided volumes (E) (n = 6 for DKO; n = 5 for CTR). F: Representative spontaneous micturition pattern of unrestrained animals.
G: Micturition volume. H: The frequency of smaller volume voids (<10 mL). The slope of the calibration curve (cm2)/volume (mL) was 0.14 (1 cm2
of area corresponds to 7.14 mL volume; n = 6 mice for each group). Data are representative of at least three different experiments and are expressed as
the means 6 SEM, by unpaired Student t test. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with age-matched control group.
Z. WANG AND ASSOCIATES
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bladder contractions during voiding was lower than for
age-matched controls (Fig. 2D). In comparison, we found
a normal pattern of bladder contraction and voiding in 12-
or 20-week-old control mice (Fig. 2A), which is in line with
other reports (14,15).
In the VSOP test, freely moving ﬂoxed control animals
showed a normal voiding pattern: voiding occurred around
the edge of the cage, and few voided urine spots appeared in
the middle of the cage (Fig. 2F) (15). However, the voided
stains for the DKO mice were much more dispersed, with
multiple urine spots away from the edge, suggesting an ab-
normal voiding pattern (15) (Fig. 2F). Notably, the micturi-
tion volumes were lower and the frequency of small volume
voids (,10 mL) was higher in DKO mice than in age-
matched controls, especially for 12-week-old DKO mice
(P , 0.01) (Fig. 2G and H). Taking the cystometric and
VSOP data together, DKO animals developed abnormal
voiding behavior with increased frequency of nonvoiding
contractions and signiﬁcantly reduced voided volumes at
the age 12 weeks, which exhibited clear signs of bladder
overactivity. For 20-week-old DKO animals, the low
amplitude of bladder contractions in tissue and cys-
tometric tests demonstrated decreased contractility at
this stage.
Characterization of systemic and local inﬂammatory
mediators in bladder tissue of DKO animals. Using the
Affymetrix GeneChips, we compared 45,000 genes in
bladder smooth muscle between the diabetic DKO and
control animals. We found 30 genes that were upregulated
1.5-fold or greater in 12-week-old DKO animals relative
FIG. 3. Increased inﬂammatory mediators in DKO mice. A: Serum soluble TNF-a level. B: Representative immunoblot of three different experi-
ments of TNF-a and TNFR1 protein levels. C: Quantiﬁcation of immunoblot protein expression by normalization to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). D: Representative immunostaining for macrophages (arrows pointed). DM, detrusor muscle; LP, lamina propria;
w, weeks. Original magniﬁcation 3400. Scale bar: 20 mm. E: Quantiﬁcation of F4/80+ macrophages in bladder tissue. The results in bar graphs are
presented as mean6 SEM, n = 5, by unpaired Student t test (A and C) or 1-way ANOVA (E). *P< 0.05, **P< 0.01, and ***P< 0.001 compared with
age-matched control group; #P < 0.05 compared with 12-week-old control. (A high-quality digital representation of this ﬁgure is available in the
online issue.)
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to age-matched controls (Supplementary Table 2). Of
these, 20 genes were inﬂammatory mediator genes that
belonged to the TNF family and were also persistently
elevated in 20-week-old mice. Because inﬂammation is
known to play an important role in the pathogenesis of
diabetic organ damage (28), we wished to determine
whether TNF-a plays any role in DBD. We found that
the serum level of TNF-a was elevated in 12- and 20-
week-old DKO animals compared with age-matched
controls (Fig. 3A), although the protein levels of 10
cytokines in urine and homogenized bladder tissue
were below the limit of detection by the Milliplex kit
assay. Western blot analysis also showed that TNF-a
and TNFR1 were signiﬁcantly upregulated in DKO blad-
der tissue, whereas TNFR2 expression did not change
(Fig. 3B and C).
Immunohistochemistry staining for the macrophage-
speciﬁc marker F4/80 further showed that F4/80+ macro-
phages signiﬁcantly increased in DKO animal bladders in
an age-dependent manner (Fig. 3D and E). Interestingly,
immunoreactivity for macrophages localized in the lamina
propria (i.e., junction between smooth muscle and epi-
thelial layers; Fig. 3D). Together, these data suggest that
circulating and bladder-localized inﬂammatory mediators
are upregulated in DKO animals.
Rho kinase activity is altered in DKO bladder smooth
muscle. Microarray analysis of bladders of 12-week-old
DKO animals demonstrated increased expression in the
genes encoding ATPase, Rho GTPase, and Rho kinase,
which are known as important regulators of cellular me-
tabolism and contractility, but decreased expression in 20-
week-old DKO mice (Supplementary Table 2). Therefore,
we next evaluated Rho kinase protein expression in bladder
smooth muscle tissue. Western blot analysis showed that
both ROCK isoforms, ROCK1 and ROCK2, were signiﬁcantly
upregulated in 12-week-old mice. In 20-week-old DKO ani-
mals, ROCK2 was signiﬁcantly downregulated compared
with age-matched controls (Fig. 4A and B). We measured
ROCK activity in bladder homogenates and further observed
that the kinase activity was elevated in 12-week-old but re-
duced in 20-week-old DKO animals (Fig. 4D). Consistent
with these changes, the level of phosphorylated MLC20
(pMLC20) was increased in 12-week-old DKO mice but de-
creased in 20-week-old DKO mice (Fig. 4C). These ﬁndings
suggest that the temporal changes in expression levels of
ROCK1 and ROCK2 correlated with the hyperactivity and
hypoactivity states of bladders in young and old DKO ani-
mals, respectively.
TNF-a directly promotes BSMC contraction. We next
addressed whether TNF-a directly contributed to the blad-
der dysfunction. Growing BSMCs from DKO and control
mice in primary tissue cultures was challenging because we
could not obtain an adequate number of cells for in vitro
experiments. Therefore, we used primary rat BSMCs, which
we were able to passage in culture. Administration of 1–30
ng/mL TNF-a for 2.5 h dramatically promoted the contrac-
tion of BSMC in a dose-dependent manner (Fig. 5A) and
upregulated pMLC20 and the phosphorylation of calmodulin
(pCalm; Fig. 5B and C). Interestingly, high glucose (22
mmol/L) treatment alone, even for 24 h, did not promote
cellular contraction (Fig. 5D). Immunostaining with pMLC20
antibody further conﬁrmed that TNF-a stimulated the
phosphorylation of MLC20 (Supplementary Fig. 1A and B).
However, pretreatment of cells with MLCK inhibitor P18
or ROCK inhibitors (Y27632 and Fasudil) for 30 min be-
fore administration of TNF-a signiﬁcantly inhibited the
ability of TNF-a to promote cell contraction (Fig. 5D and E)
and suppressed the level of pMLC20 (Supplementary Fig. 1C
and D). Our results suggest that TNF-a may augment cellular
contraction through activation of the calcium-dependent
Rho kinase–MLCK–pMLC pathway.
ROCK1 and ROCK2 mediate TNF-a–induced MLC
phosphorylation. To further investigate the signaling
pathway affected by TNF-a in BSMCs, we immunoprecipi-
tated ROCK1 and ROCK2 from BSMCs and evaluated their
activity through in vitro kinase activity assay using puri-
ﬁed MYPT-1 as a substrate. Antibodies against ROCK1 or
ROCK2 efﬁciently immunoprecipitated their presumed tar-
get (Fig. 6A). ROCK1 and ROCK2 were able to phosphorylate
MYPT-1 in the kinase assay, and this phosphorylation could
be abolished by Y27632, the Rho kinase inhibitor (Fig. 6B).
Compared with untreated cells, the activity of ROCK1 and
ROCK2 was increased by TNF-a stimulation between 5 min
and 3 h, indicating that both ROCK isoforms are activated by
TNF-a (Fig. 6C and D). However, downregulating of ROCK1
and ROCK2 with ROCK1 siRNA or ROCK2 siRNA alone, or
combined, prevented the TNF-a stimulated increase in
phosphorylation of MLC20, especially at 6 h (Fig. 6E–I).
Together, these data suggest that ROCK1 or ROCK2 is
necessary to induce MLC20 phosphorylation in response to
TNF-a stimulation.
FIG. 4. Expression of ROCK and MLC20 proteins and activity of Rho
kinase is associated with contractility in DKO bladders. A: Repre-
sentative immunoblot analysis in bladder smooth muscle extracts.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
as a loading control. B and C: Densitometric analyses of immuno-
blot. The level of ROCK1 and ROCK2 was normalized to GAPDH,
and the level of pMLC20 was expressed as a percentage of total
MLC20 protein levels. D: ROCK activity of bladder smooth muscle
homogenates, which was expressed as optical density (OD) and
normalized to control (CTR) group. Data were from three in-
dependent experiments and presented as mean 6 SEM, by Student t
test. *P < 0.05 and ***P < 0.001 compared with age-matched control
group. w, weeks.
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Neutralizing TNF-a improves bladder function in
DKO animals without effects on hyperglycemia. On
the basis of these ﬁndings, we wished to investigate whether
anti–TNF-a treatment would be a target for treating diabetes-
related bladder dysfunction. Systemic inhibition of TNF-a
activity with soluble TNFR1 (TNFRI) in DKO mice resulted
in a signiﬁcantly decreased frequency of nonvoiding con-
tractions and an increase in voided volumes compared with
untreated DKO mice (Fig. 7A, C, and D), although the fre-
quency of micturition and amplitude of voiding contractions
were not changed signiﬁcantly (P . 0.05, Fig. 7B and E).
Administration of TNFRI also improved the voiding behav-
ior of freely moving animals, as reﬂected by a more con-
trolled and organized voiding pattern, less dispersed urine
spots, larger micturition volume, and lower frequency of
small volume voids (,10 mL; Fig. 7F–H).
When determining whether the observed bladder dys-
function was associated with the concentration of circu-
lating TNF-a, we found the serum TNF-a level in DKO
mice was signiﬁcantly reduced after 6 weeks of treatment
and approached a level similar to that of the ﬂoxed control
animals (Fig. 7I). In addition, the elevated ROCK activity
as well as ROCK1 and ROCK2 protein expression in DKO
bladder smooth muscle homogenates were suppressed
(Fig. 7J). Consistent with these effects, anti–TNF-a treat-
ment not only suppressed the TNF-a expression in bladder
smooth muscle but also lowered the expression of pMLC20,
pCalm, ROCK1, ROCK2, and Rho A (Fig. 7K). Meanwhile,
anti–TNF-a treatment alone did not lower the blood glucose
level in DKO mice (Fig. 7L–N). However, administration of
the antidiabetes drug, metformin, alone or combined with
TNFRI, signiﬁcantly suppressed the blood glucose level af-
ter 6 weeks of treatment as assessed by the GTT assay (Fig.
8A–C). More important, TNFRI and metformin synergisti-
cally decreased the serum TNF-a level (Fig. 8D) and im-
proved the bladder dysfunction after 6 weeks of treatment,
as shown by a signiﬁcant decrease in frequency of non-
voiding contractions during urodynamic testing (Fig. 8E)
and a decreased number of small-volume voids in VSOP
analysis (Fig. 8F). Our results demonstrate the signiﬁcance
of targeted molecular treatment for correcting or preventing
the secondary complications of diabetes.
DISCUSSION
DBD affects 80% of diabetic patients; however, the molec-
ular mechanisms underlying DBD remain elusive due to the
lack of appropriate animal models. Bladder contraction is
mediated by cholinergic and purinergic pathways (26,29).
Here, we found phenotypic differences in the behavior of
isolated bladder strips in DKO animals. In particular, the
spontaneous activity in early-stage DKO mice (age 6 and 12
FIG. 5. TNF-a promotes BSMC contraction. A: TNF-a promoted contraction of BSMC in a dose-dependent manner. B: Representative of three
independent immunoblots of BSMCs stimulated with 1–30 ng/mL TNF-a. C: Quantiﬁcation of MLC20 phosphorylation. D: The effect of high glucose
(HG, 22 mmol/L D-glucose, Invitrogen), MLCK inhibitor peptide 18 (p18, Tocris Bioscience), ROCK inhibitor Y27632 (Enzo Life Sciences), and
Fasudil (Tocris Bioscience) on TNF-a–induced cell contraction. E: Representative cell contraction image of three independent experiments. The
cell contraction was detected after 2.5 h treatment with 10 ng/mL TNF-a, pretreated with inhibitors for 30 min or pretreated with HG for 24 h. CTR,
untreated control; Calm: total calmodulin; pCalm, phospho calmodulin. Cell contraction was determined in triplicate or quadruplicate and
expressed as the percentage of contraction, which was quantitated as the percentage of lattice size diminution relative to the area of the well. Data
are representative of three different experiments and are expressed as the means 6 SEM, by Student t test (C) or one-way ANOVA (D). ###P <
0.001 compared with untreated group; **P < 0.01 and ***P < 0.001 compared with TNF-a–treated group. (A high-quality color representation of
this ﬁgure is available in the online issue.)
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FIG. 6. ROCK1 and ROCK2 regulate TNF-a–induced MLC20 phosphorylation. A: Isoform-speciﬁc ROCK immunoprecipitation. B: Kinase activity assay.
C: Determination of ROCK activation in BSMCs after TNF-a stimulation. D: Quantiﬁcation of ROCK activity: The ROCK1 activity in untreated control
cells was deﬁned as 1, and the relative amount of ROCK1 and ROCK2 activity was presented. E–G: Augmentation of ROCK1 or ROCK2 by TNF-a
expression was inhibited by suppression of ROCK1 or ROCK2 using siRNA. BSMCs were transfected with scrambled (Scr) or ROCK1/ROCK2-targeted
siRNA for 48 h, followed by TNF-a stimulation for 1 or 6 h, and protein expression of ROCK1 or ROCK2 (E), or the level of pMLC20/MLC20 (F) was
examined by immunoblot and quantiﬁed (G). H: Quantiﬁcation of pMLC20 expression in immunostained BSMCs. The phosphorylation of MLC20 was
quantiﬁed and normalized as the ratio of pMLC20 relative to phalloidin. Data are expressed as mean 6 SEM by two-way ANOVA (G) or one-way
ANOVA (H). #P < 0.05 and ##P < 0.01 compared with scrambled group at 0 h; *P < 0.05, **P < 0.01, and ***P < 0.001 compared with TNF-a–treated
scrambled group, respectively. I: Representative immunoﬂuorescence microscopy of BSMCs of three different experiments. Scale bar: 20 mm. (A high-
quality digital representation of this ﬁgure is available in the online issue.)
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weeks) was signiﬁcantly increased, but decreased at the late
stage (age 20 weeks). These temporal changes in sponta-
neous smooth muscle activity and contractile responses to
EFS, KCl, and carbachol stimulation are consistent with
a compensation–decompensation progression of bladder
function in this animal model of type 2 diabetes, analogous
to urodynamic ﬁndings in patients with type 2 diabetes
(2,30). Because all tension data were normalized for the
length, width, and weight of the muscle strips, the response
to stimuli reﬂects an inherent change in the bladder smooth
muscle. Notably, we observed a parallel alteration in re-
sponse to EFS and direct receptor activation by carbachol,
FIG. 7. TNFRI treatment reversed bladder dysfunction of 12-week-old DKO mice. Six-week-old animals were intraperitoneally injected with
soluble TNFR1 (TNFRI, 2 mg/kg, PEG-TNFRI, Amgen), twice per week, or saline solution for controls. Blood GTT was performed before the
treatment and after 3- and 6-week treatment. After 6 weeks of treatment, half of the animals were evaluated by VSOP analysis and cystometry.
Remaining mice were killed and bladders were retrieved for protein extraction. A: Representative cystometry recordings. Arrowheads rep-
resent abnormal nonvoiding bladder contractions. B: Frequency of voiding contractions (VC). C: Frequency of nonvoiding contractions (NVC).
D: Volume of voids. E: Detrusor pressure during voiding contractions (Pdetmax). F: Representative micturition patterns of single freely moving
mice. Administration of TNFRI increased micturition volume (G) and decreased the frequency of small volume voids (<10 mL) (H). I: The level
of TNF-a in serum. J: ROCK activity in bladder smooth muscle homogenates. K: Representative immunoblot analysis. Calm, calmodulin;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase. GTT value before treatment (L) and at 3 weeks (M), and 6 weeks after treatment (N).
Data (n = 6 mice for each group) are representative of three different experiments and are expressed as the means 6 SEM, by one-way ANOVA.
*P < 0.05, **P < 0.01, and ***P < 0.001 compared with ﬂoxed control (CTR) group. #P < 0.05 and ##P < 0.01 compared with DKO nontreated
control group.
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suggesting a myogenic basis for the abnormal contraction of
DKO bladder smooth muscle. However, our ﬁndings do not
exclude a neuropathic change in bladder innervation that
may play a role in DBD in DKO animals.
Previous studies using STZ-induced type 1 diabetes models
in rats and mouse, or the Zucker type 2 diabetic and obese
rat model, have shown that diabetes in these animal models
is associated with increased bladder weight, prolonged du-
ration of bladder muscle contraction, and increased residual
rine volume (31). Work from Dr. Damaser’s Urological Bio-
mechanics Laboratory (Cleveland Clinic) has further shown
that the voiding dysfunction was only evident in Zucker
obese diabetic rats but not in Zucker nonobese diabetic rats
(31). In our study, however, we did not ﬁnd any statistical
difference in the bladder-to-body weight ratio between DKO
and age-matched control mice. We observed clear signs of
bladder overactivity for the early stage (6- and 12-week-old)
DKO mice, and hypoactivity in older (20-week-old) DKO
animals. The different mechanism in DKO mice versus
Zucker rats might cause this functional discrepancy in di-
abetic animal bladders. In the Zucker rat model, ﬁbrosis of
the external urethral sphincter, bladder wall edema, and
vasculopathy attributed to the bladder dysfunction in the
obese animals (31). In our DKO model, however, inﬂam-
mation was the main ﬁnding, especially elevated TNF-a
systemically and locally in the bladder, but without any
identiﬁable gross histologic changes, changes that are more
compatible with human patients with type 2 diabetes (32).
Studies have shown that diabetes-induced diuresis might
contribute to the bladder dysfunction by altering the nerves
and vasculature of the urinary bladder (7,9). We did not
evaluate diuresis because the voiding frequency was equiv-
alent in diabetic and nondiabetic animals and the voided
volume was even reduced in DKO diabetic mice. In addition,
absence of a diuretic response in our model could explain
why the bladder-to-body weight ratios were not changed in
our model. However, there is signiﬁcant diuresis in type 1
diabetic animal models that can partly explain the bladder
hypertrophy and increased bladder-to-body weight ratios (33).
The initiation of smooth muscle contractility is pre-
dominantly controlled by a calcium-dependent increase in
MLC20 phosphorylation (34). Activation of Rho A may be
FIG. 8. Combination of metformin (Met) and TNFRI synergistically improved the bladder dysfunction in 12-week-old DKO mice. Six-week-old
animals were treated intraperitoneally with 2 mg/kg TNFRI or saline for 6 weeks, twice weekly. Metformin (2 mg/L) was supplemented in drinking
water for the duration of the experiment. Control animals drank normal water. The effect of TNFRI+/2metformin treatment on blood glucose level
of DKO animals before treatment (A), 3 weeks after treatment (B), and 6 weeks after treatment (C). The TNF-a level in serum (D), the frequency
of nonvoiding contractions (E), and the frequency of small volume (<10 mL) voids (F) after 6 weeks of treatment (n = 6 mice for each group).
Data are representative of three different experiments and are expressed as the means 6 SEM, by one-way ANOVA. *P < 0.05, **P < 0.01, and
***P < 0.001 compared with DKO nontreated control group. #P < 0.05 compared with TNFRI-treated group.
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of particular importance and lead to subsequent activation
of Rho kinase in BSMCs (35). Here we observed that TNF-
a not only promoted the contraction of BSMCs but also
activated ROCK1 and ROCK2 and induced the phosphor-
ylation of MLC20, which suggests a close link between
TNF-a and the ROCK-signaling pathway in DBD. This as-
sociation was further conﬁrmed by anti–TNF-a treatment,
which not only improved bladder function but also sup-
pressed the TNF-a level and ROCK pathway. Generally,
these observations support an important role for TNF-a in
DKO bladder dysfunction and indicate that TNF-a may be
responsible for the observed phenotypic differences in
isolated bladder tissue and in vivo.
Given that TNF-a plays a key role in the pathogenesis of
DBD, anti-TNF therapy was expected to provide pro-
tection against the toxicity of TNF-a (36). Anti–TNF-a
reagents signiﬁcantly improved insulin resistance and re-
duced leukocyte adherence in retinal blood vessels of di-
abetic rats (37–39). In humans, however, the importance of
this mechanism is much debated because limited studies
of anti–TNF-a reagents have shown little or no effect on
the insulin-resistant state (40). Our experimental ﬁndings
match the clinical ﬁndings of Ofei et al. (40), who showed
no signiﬁcant alteration of hyperglycemia with anti–TNF-a
treatment. However, we observed signiﬁcant improvements
of the parameters associated with secondary contrac-
tions of diabetes as measured by bladder function (Fig. 7).
Moreover, our data further suggest that the beneﬁt of
anti–TNF-a therapy on DBD might be achieved through
blockade of TNF-a–induced ROCK-MLC signaling pathway
and improvement of abnormal BSMC contractility. Nota-
bly, our ﬁndings further indicate that targeted inhibition
of TNF-a combined with the oral hypoglycemic agent,
metformin, can synergistically improve the abnormalities
associated with DBD.
In conclusion, our study provides the ﬁrst demonstra-
tion that DKO mice represent a novel animal model to
investigate DBD associated with type 2 diabetes. We dem-
onstrate that the TNF-a–ROCK–pMLC pathway may repre-
sent a new target to treat patients with DBD dysfunction
and provide proof of principle that pharmacologic inhibition
of TNF-a can mitigate the urinary tract complications of
type 2 diabetes without affecting serum glucose levels.
Furthermore, the synergistic beneﬁt of metformin and
TNFRI in reversing DBD has signiﬁcant clinical implications
in long-term management of patients with type 2 diabetes.
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